Paolo Borghetti
University of Brescia
Quality of lifeInternal medicineRadiologySurgeryOncologyStage (cooking)Medical physicsGlioblastomaLung cancerHead and neck cancerChemotherapyLungDiseaseConcomitantProstate cancerToxicityNuclear medicineIn patientIncidence (epidemiology)Radiation therapyInterventional radiologyMedicine
Publications 82
#1Paolo Borghetti (University of Brescia)H-Index: 11
#2Jessica Imbrescia (University of Brescia)H-Index: 1
Last. Davide Tomasini (University of Brescia)H-Index: 4
view all 0 authors...
BACKGROUND Standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is concomitant chemoradiotherapy. The survival benefit of combined treatment is partially counterbalanced by an increased rate of acute esophageal toxicity. Several pharmaceutical products are available for prevention and management of esophagitis, including Faringel Plus. AIM To assess the incidence and the grade, identify the correlations with clinical, dosimetric, and therapeutic variables, and analyse th...
#1Anna MerlottiH-Index: 11
#2Alessio BruniH-Index: 15
Last. Stefano Arcangeli (University of Milan)H-Index: 24
view all 13 authors...
INTRODUCTION Almost 30% of non-small cell lung cancer (NSCLC) patients have locally advanced-stage disease. In this setting, definitive radiotherapy concurrent to chemotherapy plus adjuvant immunotherapy (cCRT + IO) is the standard of care, although only 40% of these patients are eligible for this approach. AIMS A comparison between cCRT and hypofractionated radiotherapy regimens (hypo-fx RT) with the addition of sequential chemotherapy (sCHT) could be useful for future combinations with immunot...
#1Giuseppe Carlo Iorio (UNITO: University of Turin)H-Index: 7
#2V. Salvestrini (UniFI: University of Florence)H-Index: 3
Last. Isacco Desideri (UniFI: University of Florence)H-Index: 17
view all 9 authors...
Abstract Introduction The historically feared radiation-induced secondary cancers and cardiac toxicities observed among mediastinal classical Hodgkin Lymphoma (cHL) patients may still negatively burden the benefit of radiotherapy among long-term survivors. Modern radiotherapy (RT) delivery techniques, including intensity-modulated RT (IMRT) and deep inspiration breath-hold (DIBH) solutions, are drastically changing this scenario. Results of a literature overview are reported and discussed in thi...
#1Lilia Bardoscia (University of Brescia)H-Index: 6
#2Luca Triggiani (University of Brescia)H-Index: 15
Last. Alessandro Antonelli (University of Brescia)H-Index: 30
view all 14 authors...
PURPOSE To retrospectively review our 20 year experience of multidisciplinary management of non-metastatic ductal prostate cancer (dPC), a rare but aggressive histological subtype of prostate cancer whose optimal therapeutic approach is still controversial. METHODS Histologically confirmed dPC patients undergoing primary, curative treatment [radical prostatectomy (RP), external beam radiotherapy (EBRT), and androgen deprivation therapy (ADT)] were included, and percentage of ductal and acinar pa...
#1Carlotta PalumboH-Index: 6
#2Alessandro Antonelli (University of Brescia)H-Index: 30
Last. Alfredo Berruti (University of Brescia)H-Index: 66
view all 13 authors...
BACKGROUND Luteinizing hormone-releasing hormone (LHRH)-agonists in prostate cancer (PCa) patients induce sarcopenic obesity. The effect of LHRH-antagonist on body composition has never been explored. We evaluated changes in fat (FBM) and lean body mass (LBM) in PCa patients undergoing Degarelix. METHODS This is a single-center prospective study, enrolling 29 non-metastatic PCa patients eligible to LHRH-antagonist from 2017 to 2019. All patients received monthly subcutaneous injection of Degarel...
1 CitationsSource
AIM Aim of this analysis is to review the role of RT in the management of several rare tumors for adult patients. METHODS Collection data regarding RT and rare tumors was made by Pubmed. RESULTS For mucosal melanomas, RT is prescribed, being associated with lower local recurrence rate. For trachea tumors, RT was used as adjuvant or salvage treatment for unresectable disease. For pNET, RT can be a suitable option for post-surgical or unresectable/borderline. For bronchopulmonary neuroendocrine tu...
#1Marco Perna (UniFI: University of Florence)H-Index: 5
#2Vieri Scotti (UniFI: University of Florence)H-Index: 19
Last. Alessio BruniH-Index: 15
view all 26 authors...
ABSTRACT Introduction : In this observational, retrospective, multi-center study, we aim to assess the safety of the combination of local metastasis-directed radiotherapy (RT) and immunotherapy in a cohort of advanced NSCLC (aNSCLC) patients. Material and Methods : We collected clinical data of aNSCLC patients who received concomitant RT and anti-PD1/PD-L1 inhibitors in seven Italian centers from September 2015 to June 2019. Concomitant RT was defined as delivered ≤4 weeks before or after the fi...
#1Giulia Marvaso (IEO: European Institute of Oncology)H-Index: 14
#2Luca NicosiaH-Index: 11
Last. Stefano Arcangeli (University of Milan)H-Index: 24
view all 12 authors...
Radiotherapy (RT) is rarely used in the palliative management of muscle-invasive bladder cancer (MIBC). This survey aims to explore current care patterns within the Italian Radiation Oncologist community on this topic. In 2020, the uro-oncological study group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) conducted a survey evaluating the RT role in advanced MIBC. An electronic questionnaire was administered online to the society members asking for: general consideration...
BACKGROUND This study analyzes patient health-related quality of life (QoL) 24-month after prostate cancer (PCa) diagnosis within the PROState cancer monitoring in ITaly from the National Research Council (Pros-IT CNR) study. METHODS Pros-IT CNR is an ongoing, longitudinal and observational study, considering a convenience sample of patients enrolled at PCa diagnosis and followed at 6, 12, 24, 36, 48 and 60 months from the diagnosis. Patients were grouped according to the treatment received: ner...
1 CitationsSource
#1A. Alghisi (Brescia University)H-Index: 1
#2Paolo Borghetti (Brescia University)H-Index: 11
Last. Luca Triggiani (Brescia University)H-Index: 15
view all 16 authors...
Solitary plasmacytoma (SP) is characterized by a single mass of clonal plasma cells. Definitive RT can result in long-term local control of the SP. Due to the small number of patients and narrow range of doses, phase III randomized trials are lacking. The aim of this study is to further support the potential use of RT for the treatment of SP. Clinical data of all patients treated for SP at our Institution between 1992 and 2018 were reviewed. A total of 42 consecutive patients were analyzed. The ...